FDA Approved: GABAPENTIN — Supplemental Application (Exelan Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Gabapentin from Exelan Pharmaceuticals, Inc. (ANDA 090705).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Postherpetic Neuralgia

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

SUPPL AP for GABAPENTIN (GABAPENTIN)